Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06659549 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
A Phase 2 study of Geographic Atrophy of the Macula, sponsored by Galimedix Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
- 14
- Study locations
NCT06659549 is a Phase 2 study of Geographic Atrophy of the Macula that is actively recruiting participants, run by Galimedix Therapeutics. The registered enrollment target is 110 participants. The trial reports 14 study locations across 4 states.
The verdict
NCT06659549, a Phase 2 study of Geographic Atrophy of the Macula, is actively recruiting participants, sponsored by Galimedix Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
- 14
- Study locations
Study Summary
Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina. This means that there is an area with a loss of light-sensitive cells, called photoreceptors. That part of the retina can no longer see. Atrophy begins as a small spot in the retina distant from the fovea which is the part of the retina responsible for sharp central vision. The GA grows, and when it reaches the fovea, vision is severely diminished, and details cannot be seen anymore. The purpose of the eDREAM study is to understand if GAL-101 can slow the growth of GA and prevent it from reaching the fovea. GAL-101 is given as eyedrops. eDREAM patients will administer study eyedrops every day. Patients will be assigned by chance (randomly) to receive either eye-drops that contain the new medication, GAL-101, or eyedrops without the active drug (Placebo). Neither patients nor doctors will know which treatment was assigned to each patient until the end of the study.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GAL-101
Study Locations (14)
Other
- Ophthalmological Center After S.V. Malayan - Yerevan
- Centre Monticelli Paradis d'Ophtalmologie - Marseille
- Akhali Mzera Limited - Tbilisi
- Caucasus Medical Centre LLC - Tbilisi
- Chichua Medical Centre Mzera LLC - Tbilisi
- Universitäts-Augenklinik Bonn - Bonn
- Institute of Eye Surgery (IOES Waterford) - Waterford
- Hadassah Medical Center - Jerusalem
- Tel Aviv Medical Center - Tel Aviv
California
- Retina-Vitreous Associates Medical Group - Beverly Hills
- Bay Area Retina Associates - Walnut Creek
Milano
- Medical Retina & Imaging Unit, IRCCS MultiMedica, Ospedale San Giuseppe - Milan
- Unità di Oculistica, IRCCS Ospedale San Raffaele - Milan
Maryland
- Cumberland Valley Retina Consultants - Hagerstown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2025-01-10 |
| Est. Completion | 2027-05-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06659549
The ClinicalTrials.gov registry entry for NCT06659549 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galimedix Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Geographic Atrophy of the Macula appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06659549 reports 14 study locations spanning 4 distinct geographic areas - top geographies include Other, California, Milano.
Frequently Asked Questions
What is clinical trial NCT06659549 about?
NCT06659549 is a clinical study titled "A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD". Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina. This means that there is an area with a loss of light-sensitive cells, called photoreceptors. That part of the retina can no longer see. Atrophy begins as a sma...
What is the current status of trial NCT06659549?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2025-01-10. Estimated completion is 2027-05-30.
What conditions does trial NCT06659549 study?
This clinical trial studies the following conditions: Geographic Atrophy of the Macula.
What interventions are being tested in trial NCT06659549?
The interventions under investigation include: Placebo (DRUG), GAL-101 (DRUG).
Who is sponsoring clinical trial NCT06659549?
This trial is sponsored by Galimedix Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06659549 being conducted?
This trial has 14 study locations across California, Maryland, Milano. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Geographic Atrophy of the Macula
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.